Information Opacity in Biopharmaceutical Innovation Through the Lens of COVID-19.
Am J Law Med
; 47(2-3): 157-175, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1361581
ABSTRACT
The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Patents as Topic
/
Biological Products
/
Drug Approval
/
Therapies, Investigational
/
COVID-19 Drug Treatment
/
Government Agencies
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Am J Law Med
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS